XML 274 R217.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Segment information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details) € in Millions, $ in Millions | 1 Months Ended | 12 Months Ended
--- | --- | ---
Nov. 30, 2022 EUR (€) | Nov. 30, 2022 USD ($) | Dec. 31, 2024 EUR (€) | Dec. 31, 2023 EUR (€) | Dec. 31, 2022 EUR (€)
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |
Net income attributable to non-controlling interests |  |  |  | € 58 | € 36 | [1],[2] | € 113 | [1],[2]
Fair value remeasurement of contingent consideration |  |  |  | (96) | (93) | [2] | 27 | [2]
Restructuring costs and similar items |  |  |  | (1,396) | (1,030) | [2],[3] | (1,077) | [2],[3]
Other gains and losses, and litigation |  |  |  | (470) | (196) | [2] | (143) | [2]
Operating income |  |  |  | 7,252 | 6,960 | [2],[4] | 10,162 | [2],[4],[5]
Financial expenses |  |  |  | (1,073) | (1,293) | [2],[4],[6] | (430) | [2],[4],[5],[6]
Financial income |  |  |  | 519 | 584 | [2],[4],[6] | 205 | [2],[4],[5],[6]
Income before tax and investments accounted for using the equity method |  |  |  | 6,698 | 6,251 | [2],[4],[7] | 9,937 | [2],[4],[5],[7]
Immuno-oncology collaboration agreement | Regeneron Pharmaceuticals, INC |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |
Regular milestone payments for projects under collaboration agreements |  | € 96 | $ 100 |  |  |  |  |
Other intangible assets |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  |  |  | 265 | 932 |  | (454) |
Other intangible assets | NK Cell and ProXTen technology platforms |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  |  |  |  | 833 |  |  |
Other intangible assets | SAR444245 |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  |  |  |  |  |  | 1,586 |
Eloctate [Member] |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |
Reversal amount |  |  |  |  |  |  | 2,154 |
Eloctate [Member] | Research and development projects and technology platforms |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |
Reversal amount |  |  |  |  |  |  | 600 |
Impairment of other intangible assets, net of reversals (excluding software) |  |  |  |  |  |  | 600 |
Biopharma (operating segment) |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  |  |  | 415 |  |  |  |
Biopharma (operating segment) | Other intangible assets |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  |  |  | 225 |  |  |  |
Biopharma (operating segment) | Research and development projects and technology platforms |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  |  |  | 640 |  |  |  |
Biopharma (operating segment) | Clinical Study |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  |  |  | 239 |  |  |  |
Operating segments |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |
Business operating income |  |  |  | 11,343 | 11,178 | [4] | 12,793 | [4],[5]
Material reconciling items |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |
Share of profit/(loss) from investments accounted for using the equity method | [8] |  |  | (136) | (101) | [4] | (76) | [4],[5]
Net income attributable to non-controlling interests | [9] |  |  | 14 | 18 | [4] | 16 | [4],[5]
Amortization and impairment of intangible assets | [10] |  |  | (1,997) | (2,807) | [4] | (1,375) | [4],[5]
Fair value remeasurement of contingent consideration |  |  |  | (96) | (93) | [4] | 27 | [4],[5]
Expenses arising from the impact of acquisitions on inventories | [11] |  |  | (10) | (9) | [4] | (3) | [4],[5]
Restructuring costs and similar items | [12] |  |  | (1,396) | (1,030) | [4] | (1,077) | [4],[5]
Other gains and losses, and litigation | [13] |  |  | € (470) | € (196) | [4] | € (143) | [4],[5]
[1] | Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations).
[2] | Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[3] | (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[4] | (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[5] | 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€706 million net of tax)
[6] | (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[7] | (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[8] | (b)Joint ventures and associates with which Sanofi has entered into a strategic alliance.
[9] | (c)Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests.
[10] | (d)For 2024, this line includes a net impairment charge of €248 million mainly due to a recognition of impairment losses of €640 million against on various research and development projects – including a €239 million loss resulting from the decision taken in February 2025 to discontinue a phase 3 clinical study investigating of a vaccine candidate to prevent invasive E.coli disease - partially offset by impairment losses reversals, recognized in connection with the disposals of the ProXTen platform and Enjaymo, for €225 million and €167 million respectively. For 2023, this amount mainly comprises an impairment loss of €833 million, reflecting the impact of the strategic decision to de-prioritize certain R&D programs, in particular those related to the NK Cell and ProXTen technology platforms. For 2022, this line includes a reversal of €2,154 million on Eloctate franchise products following FDA approval of ALTUVIIIO on February 22, 2023, partially offset by an impairment loss of €1,586 million on intangible assets relating to SAR444245 (non- alpha interleukin-2).
[11] | (e)This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.
[12] | (f) See note D.27
[13] | (g)See note D.28.

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 98 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_b&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ExpenseOfRestructuringActivities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of costs associated with financing activities of the entity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 82 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_FinanceCosts
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of income associated with interest and other financing activities of the entity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 85 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_FinanceIncome
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The increase (decrease) in a contingent consideration asset (liability) relating to a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2023-01-01 -Paragraph B67 -Subparagraph b -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_b_i&doctype=Appendix&subtype=B -URIDate 2023-03-23 + Details
Name: | ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2023-01-01 -Paragraph 12 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_e&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 81B -Subparagraph a -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_i&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ProfitLossAttributableToNoncontrollingInterests
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The profit (loss) from operating activities of the entity. [Refer: Profit (loss)] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 32 -IssueDate 2023-01-01 -Paragraph IE33 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 85 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ProfitLossFromOperatingActivities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Paragraph 28 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard -URIDate 2023-03-23 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2023-01-01 -Paragraph 23 -Subparagraph g -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_g&doctype=Standard -URIDate 2023-03-23 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 82 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_c&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amortization and impairment of intangible assets other than goodwill. + References No definition available. + Details
Name: | sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Business operating income. + References No definition available. + Details
Name: | sny_BusinessOperatingIncome
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Expenses arising from the impact of acquisitions on inventories. + References No definition available. + Details
Name: | sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Impairment loss on intangible assets other than goodwill. + References No definition available. + Details
Name: | sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Impairment Loss Recognised In Profit Or Loss, Intangible Assets Other Than Goodwill, Reversal Amount + References No definition available. + Details
Name: | sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Income before tax and investments accounted for equity method investments. + References No definition available. + Details
Name: | sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.] + References No definition available. + Details
Name: | sny_OtherGainsLossesAndLitigation
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Regular Milestone Payments For Projects Under Collaboration Agreements + References No definition available. + Details
Name: | sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | sny_PrincipalAlliancesAxis=sny_ImmunoOncologyCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_NKCellAndProXTenTechnologyPlatformsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_SAR444245Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sny_EloctateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ResearchAndDevelopmentProjectsAndTechnologyPlatformsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sny_BiopharmaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_ClinicalStudyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_MaterialReconcilingItemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |